Ignacio Massone
CEO and co-founder
Resistia Corporation
I'm working on
3 months ago
Restoring the efficacy of first-line/existing antibiotics and enabling natural immune clearance of chronic infections; using molecules from healthy microbiota to disarm mature biofilm structures.
I'm looking for
3 months ago
Partnering and collaborating with Pharma and Biopharma industry players and advisors: medical, regulatory, CRO and CMC. Human & Animal Health. Biotechnology R&D services, Out-licensing, Professional services and consulting.
About
GridX VC 2025: Backed by LatAm's leading deep-tech company builder, providing our initial pre-seed funding and operational structuring.
MIT (The Engine - Blueprint 2026 cohort): Selected for Boston's premier "Tough Tech" program, validating our disruptive approach and market scalability.
SynBioBeta 2026 and SOSV (US): Selected to pitch our solution platform to the global synthetic biology and advanced bio-manufacturing community.
10th Global AMR Conference 2026 (Basel): Selected as Top Innovators and Pitching Finalists, validating our platform's mechanism of action and commercial strategy among global pharma and infectious disease experts.
BioSpain Oct 2026: pitching finalist in the upcoming conference.
Ignacio Massone
CEO and co-founder
Resistia CorporationWork experience
CEO and co-founder
GSK
Business Manager
2018 - 2025
Top industry applications
Open to opportunities in
AntimicrobialsBiofilmsBioinformaticsBiomimeticsBiotechnologyImmunotherapy
Last updated Jul 2026
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.